Image

Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial

Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage.

Description

Objective

To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage.

Design

This study is a multi-center, prospective, double-blinded, randomized controlled trial.

Interventions

First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml of nicardipine hydrochloride is injected into the EVD or LD drain tube, followed by 2 ml of 0.9 % sodium chloride solution (NaCl), and then the EVD or LD tube was clamped for 2 hours after the injection was completed, then kept open as clinically necessary until the next dose (twice a day).

Eligibility

Inclusion criteria:

  1. Age 18-80.
  2. Spontaneous SAH confirmed by head CT.
  3. Saccular brain aneurysm is identified and treated, either surgically or endovascularly.
  4. SAH Fisher grade \>1 or modified Fisher grade \>0.
  5. EVD placed for acute hydrocephalus, or LD placed for draining bloody CSF as deemed necessary by the treating physician.
  6. Any clinical scenario leading to the diagnosis of possible vasospasm, which includes:
    1. Mean flow velocity of MCA \>120, or Lindegaard Ratio ( LR ) \> 3.
    2. Any intracranial artery including MCA, ACA, PCA, and BA, TCD showed an upward trend of mean flow velocity for 2 consecutive days (\>25cm/s/day).
    3. Clinical deterioration including mental status change (GCS score decrease \> 2) and focal neurological deficit unable to be attributed to other known neurological reasons.
    4. Evidence of vasospasm on CTA or DSA, or ischemic change by CTP, MRI.
  7. Within 14 days of onset of SAH.
  8. Informed consent obtained from the patient or family member.

Exclusion criteria:

  1. Hunt-Hess Grade 5 or WFNS Grade 5 (no clinical improvement after EVD placement for acute hydrocephalus).
  2. Bacterial or distal aneurysms without subarachnoid hemorrhage in the basal cisterns.
  3. The treating physician determines that the culprit aneurysm has not been fully repaired, with a very high likelihood of rebleeding in the near term.
  4. History of head trauma within the past 3 months.
  5. Any recent brain disease within 3 months, such as tumors, stroke, epilepsy, vasculitis, arteriovenous malformation, hydrocephalus, etc.
  6. History of psychiatric disorders or seizures within 3 months.
  7. Severe concurrent medical conditions.
  8. Pregnant women or those of childbearing potential with a positive urine or serum β-human chorionic gonadotropin (HCG) test.
  9. Lactating women.
  10. Life expectancy of less than 1 year prior to aSAH onset.
  11. Pre-morbid mRS score \>1.
  12. Participation in another randomized clinical trial that may confound the evaluation of this study.

Study details
    Aneurysmal Subarachnoid Hemorrhage
    Vasospasm

NCT06329635

The Affiliated Hospital Of Guizhou Medical University

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.